Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
Dianthus Therapeutics reported a quarterly loss of $0.81 per share, compared with the Zacks consensus estimate of a $1.00 loss. The company reported a loss of $0.97 per share a year earlier.
Why it matters — DNTH watchers may note the reported loss was smaller than the consensus estimate and than the year-ago loss.